Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821762 | 1.00 | MRGPRX4 (0.31) | MRGPRX4NR3C1 | |
| SCHEMBL4821769 | 1.00 | MRGPRX4 (0.31) | MRGPRX4NR3C1 | |
| SCHEMBL4816857 | 0.83 | NR3C1 (0.42) | MRGPRX4NR3C1 | |
| SCHEMBL4816853 | 0.83 | NR3C1 (0.42) | MRGPRX4NR3C1 | |
| SCHEMBL4816865 | 0.83 | NR3C1 (0.42) | MRGPRX4NR3C1 | |
| SCHEMBL4821088 | 0.83 | MRGPRX4 (0.40) | MRGPRX4NR3C1 | |
| SCHEMBL4821113 | 0.83 | MRGPRX4 (0.40) | MRGPRX4NR3C1 | |
| SCHEMBL4821100 | 0.83 | MRGPRX4 (0.40) | MRGPRX4NR3C1 | |
| SCHEMBL4823447 | 0.81 | MRGPRX4 (0.43) | MRGPRX4NR3C1 | |
| SCHEMBL4823435 | 0.81 | MRGPRX4 (0.43) | MRGPRX4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | MRGPRX4 451/4885NR3C1 2380/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | MRGPRX4 451/4885NR3C1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.